Invivyd Inc. (IVVD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
This Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?
Invivyd (NASDAQ: IVVD), a biopharmaceutical company focused on developing protection against serious viral infectious diseases, is back in the spotlight with notable share price movement.
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago.
Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Katie Falzone - Senior Vice President, Finance Marc Elia - Chairman Tim Lee - Chief Commercial Officer Bill Duke - Chief Financial Officer Dr. Robert Allen - Chief Scientific Officer Dr. Mark Wingertzahn - Senior Vice President, Clinical Development Conference Call Participants Kyle Yang - Jefferies Luis Santos - H.C. Wainwright Operator Thank you for standing by.
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago.
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago.
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
On Monday, the FDA declined Invivyd, Inc.'s IVVD request to expand the existing emergency use authorization (EUA) for pre-exposure prophylaxis of COVID-19 EUA for Pemgarda (pemivibart) for mild-to-moderate COVID-19 in adults and adolescents who have moderate-to-severe immune compromise.
I See The Bull Case For Invivyd, But I'm Not Married To It
Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval.
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:18 AM ET Invivyd, Inc. (NASDAQ:IVVD ) Q3 2024 Earnings Conference Call November 14, 2024, 08:30 AM ET Company Participants Marc Elia - Chairperson, Board of Directors and Executive Committee Tim Lee - COO Bill Duke - CFO Robert Allen - CSO Mark Wingertzahn - SVP of Clinical Development and Medical Affairs Katie Falzone - VP, Corporate Controller Conference Call Participants Maxwell Skor - Morgan Stanley Michael Yee - Jefferies Jason Kolbert - D. Boral Capital Luis Santos - H.C.
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.36 per share a year ago.
Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Katie Falzone - VP, Corporate Controller Marc Elia - Chairperson, Board of Directors and Executive Committee Tim Lee - Chief Commercial Officer Bill Duke - CFO Robert Allen - Chief Scientific Officer Mark Wingertzahn - SVP of Clinical Development and Medical Affairs. Conference Call Participants Boran Wang - Guggenheim Securities Maxwell Skor - Morgan Stanley Operator Good day, and welcome to the Second Quarter Invivyd Earnings Conference Call.
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.46 per share a year ago.
